Gu, Phillip http://orcid.org/0000-0003-4819-8979
Dube, Shishir
Lee, YooJin
Yang, Shaohong
Li, Dalin
Haritunians, Talin
Vasiliauskas, Eric
Bonthala, Niru
Syal, Gaurav
Yarur, Andres
Ziring, David
Targan, Stephan
Rabizadeh, Shervin
Melmed, Gil Y.
Fleshner, Phillip
McGovern, Dermot P. B.
Funding for this research was provided by:
American College of Gastroenterology (ACG-CR-040-2022)
National Institute of Diabetes and Digestive and Kidney Diseases (U01 2299170)
Leona M. and Harry B. Helmsley Charitable Trust (2352240)
Cedars-Sinai Medical Center
Article History
Received: 6 July 2023
Accepted: 9 November 2023
First Online: 28 November 2023
Declarations
:
: PG had no conflicts of interests to disclose. SD had no conflicts of interest to disclose. YL had no conflicts of interest to disclose. SY had no conflicts of interest to disclose. DL has received consulting fees from Prometheus Biosciences Inc.. TH had no conflicts of interest to disclose. EV had no conflicts of interest to disclose. NB had no conflicts of interest to disclose. GS receives research support from Pfizer. AY has received consulting fees from Bristol Myers Squibb, Arena, Pfizer, Takeda, and Landos. DZ is on the speaking bureau for AbbVie, Prometheus Labs, and Regeneron. ST serves on the scientific advisory board for Seaver Foundation for Austim and has stock options in Promethus Biosciences Inc. PF has received consulting fees from Takeda. SR has received advisory fees from Prometheus and Janssen. GYM has received consulting fees from Abbvie, Arena Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dieta, Entasis, Fresenius Kabi, Genentech, Gilead, Janssen, Medtronic, Merck, Oshi, Prometheus Labs, Pfizer, Takeda, and Techlab. DPBM has received consulting fees from Gilead, Takeda, Pfizer, Boehringer Ingelheim, Qu Biologics, Bridge Biotherapeutics, Prometheus Biosciences Inc. (now owned by MERCK), and Prometheus Labs.